The clinical characteristics and prognosis of patients with SAPHO syndrome--a real-world cohort study

被引:4
|
作者
Duan, Hongji [1 ]
Gao, Shuang [2 ]
Zhang, Lihua [3 ]
Song, Le [4 ]
Zhai, Jiayu [5 ]
Deng, Xiaoli [1 ]
机构
[1] Capital Med Univ, Beijing Jishuitan Hosp, Dept Orthoped Med, 31 Xinjiekou East St, Beijing 100035, Peoples R China
[2] Peking Univ Third Hosp, Lymphoma Ctr, Dept Hematol, Beijing, Peoples R China
[3] Peking Univ Third Hosp, Dept Radiol, Beijing, Peoples R China
[4] Peking Univ Third Hosp, Dept Nucl Med, Beijing, Peoples R China
[5] Peking Univ Third Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
关键词
Iguratimod; Outcome; SAPHO syndrome; Treatment; NF-KAPPA-B; OSTEITIS SAPHO; SINGLE-CENTER; HYPEROSTOSIS; PUSTULOSIS; ACNE; SYNOVITIS; CELLS; T-614; BONE;
D O I
10.1007/s10067-023-06782-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesWe aimed to analyze the clinical characteristics and outcomes of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.MethodsThe clinical records of 64 patients with SAPHO syndrome were collected, and the treatment and outcomes of 27 patients were followed up. The patients were divided into three groups according to the site of bone lesions: only anterior chest wall (ACW) involvement, only spinal involvement, and bone lesion involvement at both sites. The clinical characteristics and outcomes were compared. The clinical characteristics of the patients with and without peripheral joint involvement were compared.ResultsAmong all patients, 31.25% (20/64) had only ACW involvement, 15.63% (10/64) had only spinal involvement, and 53.12% (34/64) had both ACW and spinal involvement. Peripheral joint involvement was observed in 25.00% (16/64) of the patients. Patients with only spinal involvement were older than those with only ACW involvement (p = 0.006). Patients with both ACW and spinal involvement were older than those with only ACW involvement (p = 0.002) and had a longer diagnosis delay (p = 0.015). Patients with peripheral joint involvement were younger than those without peripheral joint involvement (p = 0.028). During follow-up, 88.89% (24/27) of patients had good outcomes. Twenty-two patients were treated with non-steroidal anti-inflammatory drugs + Iguratimod (IGU), and the outcomes of 90.91% (20/22) improved.ConclusionsA relationship may exist between the sites of bone lesions and clinical characteristics of patients with SAPHO syndrome. The clinical outcomes of these patients may be good, and IGU may be effective in treating SAPHO syndrome.Key Points center dot This study is the first long-term follow-up on the effectiveness of iguratimod in treating patients with SAPHO.center dot This study revealed that patients with SAPHO and different bone lesion sites may present with different clinical characteristics.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 50 条
  • [41] Achievement of long-term lipid targets in a cohort of patients with acute coronary syndrome in real-world clinical practice
    Conde, C. Baldeon
    Martinez, N. Royuela
    Ibarbia, C. Garcia
    Ruiz, A. R. Guerra
    Miguel, I. Olavarri
    Belaustegui, M. Cobo
    Lavin, B. Alio
    Vilchez, F. J. Gonzalez
    Hernandez, J. M. de la Torre
    Hernandez, J. L. Hernandez
    REVISTA CLINICA ESPANOLA, 2023, 223 (04): : 223 - 230
  • [42] Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world setting
    Sadetsky, N.
    Corvino, F.
    Surinach, A.
    Goodman, G.
    MELANOMA RESEARCH, 2016, 26 : E42 - E42
  • [43] Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics
    Heerlein, K.
    Young, A. H.
    Otte, C.
    Frodl, T.
    Degraeve, G.
    Hagedoorn, W.
    Oliveira-Maia, A. J.
    Sola, V. Perez
    Rathod, S.
    Rosso, G.
    Sierra, P.
    Morrens, J.
    Dooren, G. Van
    Gali, Y.
    Perugi, G.
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 283 : 115 - 122
  • [44] Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab
    Ling, Gavin
    Ajidahun, Aderonke
    Austin, Steve K.
    Dolan, Gerard
    McCormick, Aine
    BLOOD, 2020, 136
  • [45] Real-World Characteristics, Treatment Utilization, and Transfusion Burden in Patients with β-Thalassemia Initiating Luspatercept: A US Cohort Study
    Sheth, Sujit
    Glassberg, Mrudula B.
    Lee, Jana
    Ip, Queeny
    Liu, Jingyuan
    Bueno, Luciana Moro
    BLOOD, 2023, 142
  • [46] PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH MANTLE CELL LYMPHOMA IN CHINA: A REAL-WORLD, CONTEMPORARY COHORT STUDY
    Liu, Y.
    Bao, Y.
    Chen, Y.
    Zhou, J.
    VALUE IN HEALTH, 2024, 27 (06) : S162 - S162
  • [47] CHARACTERISTICS OF ADULT MASH PATIENTS AND FACTORS ASSOCIATED WITH MASH-RELEVANT CLINICAL ENDPOINTS IN A REAL-WORLD US COHORT
    Newsome, Philip
    Barritt, Alfred, IV
    Morris, Heather
    Yu, Feng
    Mospan, Andrea
    Karmarkar, Taruja
    Melaragno, Matthew
    Zhang, Xiao
    Cheng, Mickie
    Fernandes, Gail
    Sanyal, Arun
    HEPATOLOGY, 2024, 80 : S863 - S864
  • [48] Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database
    Eule, Corbin J.
    Warren, Adam
    Kuna, Elizabeth Molina
    Robin, Tyler P.
    Gershman, Boris
    Kim, Simon P.
    Flaig, Thomas W.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [49] Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real-world data
    Rahhal, Alaa
    Khir, Fadi
    Aljundi, Amer Hussien
    AlAhmad, Yaser
    Alzaeem, Hakam
    Habra, Masa
    Al-Shekh, Israa
    Mahfouz, Ahmed
    Awaisu, Ahmed
    Al-Yafei, Sumaya
    Arabi, Abdul Rahman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 2043 - 2052
  • [50] Comparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real-World Scenario: A Cohort Study
    Wang, Xiao-Peng
    Li, Jing-Jie
    Wang, Qian-Nan
    Gao, Gan
    Yu, Dan
    Zhang, Qian
    Liu, Si-Meng
    Wang, Min-Jie
    Bao, Xiang-Yang
    Duan, Lian
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (12)